BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
68.25
-0.48 (-0.70%)
At close: Feb 21, 2025, 4:00 PM
67.75
-0.50 (-0.73%)
After-hours: Feb 21, 2025, 7:16 PM EST
BioMarin Pharmaceutical Revenue
In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth. BioMarin Pharmaceutical had revenue of $747.31M in the quarter ending December 31, 2024, with 15.65% growth.
Revenue (ttm)
$2.85B
Revenue Growth
+17.97%
P/S Ratio
4.54
Revenue / Employee
$839,140
Employees
3,401
Market Cap
13.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BMRN News
- 2 days ago - Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
- 2 days ago - BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 days ago - BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance - PRNewsWire
- 17 days ago - BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET - PRNewsWire
- 4 weeks ago - BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy - Seeking Alpha
- 5 weeks ago - BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court - PRNewsWire
- 6 weeks ago - BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA - PRNewsWire
- 3 months ago - Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call - Seeking Alpha